191 related articles for article (PubMed ID: 15826765)
1. Insulin-like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival.
Inman BA; Harel F; Audet JF; Meyer F; Douville P; Fradet Y; Lacombe L
Eur Urol; 2005 May; 47(5):695-702. PubMed ID: 15826765
[TBL] [Abstract][Full Text] [Related]
2. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above.
Kupelian PA; Buchsbaum JC; Elshaikh M; Reddy CA; Zippe C; Klein EA
Cancer; 2002 Dec; 95(11):2302-7. PubMed ID: 12436435
[TBL] [Abstract][Full Text] [Related]
3. Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen.
San Francisco IF; Regan MM; Olumi AF; DeWolf WC
J Urol; 2004 Apr; 171(4):1492-9. PubMed ID: 15017206
[TBL] [Abstract][Full Text] [Related]
4. Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening.
Oliver SE; Holly J; Peters TJ; Donovan J; Persad R; Gillatt D; Pearce A; Hamdy FC; Neal DE; Gunnell D
Urology; 2004 Aug; 64(2):317-22. PubMed ID: 15302487
[TBL] [Abstract][Full Text] [Related]
5. Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer.
Miyata Y; Sakai H; Hayashi T; Kanetake H
Prostate; 2003 Feb; 54(2):125-32. PubMed ID: 12497585
[TBL] [Abstract][Full Text] [Related]
6. Preoperative PSA level significantly associated with interval to biochemical progression after radical retropubic prostatectomy.
Gonzalez CM; Roehl KA; Antenor JV; Blunt LW; Han M; Catalona WJ
Urology; 2004 Oct; 64(4):723-8. PubMed ID: 15491709
[TBL] [Abstract][Full Text] [Related]
7. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
Magheli A; Rais-Bahrami S; Peck HJ; Walsh PC; Epstein JI; Trock BJ; Gonzalgo ML
J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095
[TBL] [Abstract][Full Text] [Related]
8. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
9. Preoperative insulin-like growth factor-binding protein-3 (IGFBP-3) blood level predicts gleason sum upgrading.
Terracciano D; Bruzzese D; Ferro M; Mazzarella C; Di Lorenzo G; Altieri V; Mariano A; Macchia V; Di Carlo A
Prostate; 2012 Jan; 72(1):100-7. PubMed ID: 21520165
[TBL] [Abstract][Full Text] [Related]
10. Invasion of seminal vesicles by adenocarcinoma of the prostate: PSA outcome determined by preoperative and postoperative factors.
Bloom KD; Richie JP; Schultz D; Renshaw A; Saegaert T; D'amico AV
Urology; 2004 Feb; 63(2):333-6. PubMed ID: 14972484
[TBL] [Abstract][Full Text] [Related]
11. Serum measurements of testosterone, insulin-like growth factor 1, and insulin-like growth factor binding protein-3 in the diagnosis of prostate cancer among Korean men.
Hong SK; Han BK; Jeong JS; Jeong SJ; Moon KH; Byun SS; Lee SE
Asian J Androl; 2008 Mar; 10(2):207-13. PubMed ID: 18097534
[TBL] [Abstract][Full Text] [Related]
12. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
[TBL] [Abstract][Full Text] [Related]
13. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort.
Tahir SA; Frolov A; Hayes TG; Mims MP; Miles BJ; Lerner SP; Wheeler TM; Ayala G; Thompson TC; Kadmon D
Clin Cancer Res; 2006 Aug; 12(16):4872-5. PubMed ID: 16914574
[TBL] [Abstract][Full Text] [Related]
14. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
15. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
16. Should we replace the Gleason score with the amount of high-grade prostate cancer?
Vis AN; Roemeling S; Kranse R; Schröder FH; van der Kwast TH
Eur Urol; 2007 Apr; 51(4):931-9. PubMed ID: 16935413
[TBL] [Abstract][Full Text] [Related]
17. Prediction of prostate-specific antigen recurrence in men with long-term follow-up postprostatectomy using quantitative nuclear morphometry.
Veltri RW; Miller MC; Isharwal S; Marlow C; Makarov DV; Partin AW
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):102-10. PubMed ID: 18199716
[TBL] [Abstract][Full Text] [Related]
18. Comparison of biochemical relapse-free survival between primary Gleason score 3 and primary Gleason score 4 for biopsy Gleason score 7 prostate cancer.
Burdick MJ; Reddy CA; Ulchaker J; Angermeier K; Altman A; Chehade N; Mahadevan A; Kupelian PA; Klein EA; Ciezki JP
Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1439-45. PubMed ID: 18963536
[TBL] [Abstract][Full Text] [Related]
19. Preoperative neural network using combined magnetic resonance imaging variables, prostate-specific antigen, and Gleason score to predict positive surgical margins.
Poulakis V; Witzsch U; de Vries R; Emmerlich V; Meves M; Altmannsberger HM; Becht E
Urology; 2004 Sep; 64(3):516-21. PubMed ID: 15351582
[TBL] [Abstract][Full Text] [Related]
20. Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy.
Yamamoto S; Yonese J; Kawakami S; Ohkubo Y; Tatokoro M; Komai Y; Takeshita H; Ishikawa Y; Fukui I
Eur Urol; 2007 Sep; 52(3):696-701. PubMed ID: 17412490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
